Literature DB >> 23222785

What's fueling the biotech engine-2011 to 2012.

Saurabh Rob Aggarwal1.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23222785     DOI： 10.1038/nbt.2437

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  12 in total

1.  Is maintenance rituximab now ready for PRIMA-time?

Authors:  Paul A Hamlin
Journal:  Curr Oncol Rep       Date:  2010-11       Impact factor: 5.075

2.  Targeted cancer therapies.

Authors:  Saurabh Aggarwal
Journal:  Nat Rev Drug Discov       Date:  2010-06       Impact factor: 84.694

3.  What's fueling the biotech engine-2009-2010.

Authors:  Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2010-11       Impact factor: 54.908

4.  What's fueling the biotech engine--2008.

Authors:  Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2009-11       Impact factor: 54.908

5.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

Authors:  Ronald F van Vollenhoven; Roy Fleischmann; Stanley Cohen; Eun Bong Lee; Juan A García Meijide; Sylke Wagner; Sarka Forejtova; Samuel H Zwillich; David Gruben; Tamas Koncz; Gene V Wallenstein; Sriram Krishnaswami; John D Bradley; Bethanie Wilkinson
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

6.  Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2011-06-07       Impact factor: 54.908

7.  U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

Authors:  R Angelo de Claro; Karen McGinn; Virginia Kwitkowski; Julie Bullock; Aakanksha Khandelwal; Bahru Habtemariam; Yanli Ouyang; Haleh Saber; Kyung Lee; Kallappa Koti; Mark Rothmann; Marjorie Shapiro; Francisco Borrego; Kathleen Clouse; Xiao Hong Chen; Janice Brown; Lara Akinsanya; Robert Kane; Edvardas Kaminskas; Ann Farrell; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2012-09-07       Impact factor: 12.531

8.  Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

Authors:  William J Sandborn; Subrata Ghosh; Julian Panes; Ivana Vranic; Chinyu Su; Samantha Rousell; Wojciech Niezychowski
Journal:  N Engl J Med       Date:  2012-08-16       Impact factor: 91.245

9.  Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.

Authors:  Bernard Zinman; Greg Fulcher; Paturi V Rao; Nihal Thomas; Lars A Endahl; Thue Johansen; Rebecka Lindh; Andrew Lewin; Julio Rosenstock; Michel Pinget; Chantal Mathieu
Journal:  Lancet       Date:  2011-03-12       Impact factor: 79.321

Review 10.  Bevacizumab in the treatment of ovarian cancer.

Authors:  Florian Heitz; Philipp Harter; Jana Barinoff; Bianca Beutel; Paevi Kannisto; Jacek P Grabowski; Julia Heitz; Christian Kurzeder; Andreas du Bois
Journal:  Adv Ther       Date:  2012-08-21       Impact factor: 3.845
View more
  20 in total

Review 1.  Why we need GMO crops in agriculture.

Authors:  Melvin J Oliver
Journal:  Mo Med       Date:  2014 Nov-Dec

2.  Enriched protein screening of human bone marrow mesenchymal stromal cell secretions reveals MFAP5 and PENK as novel IL-10 modulators.

Authors:  Jack M Milwid; Jessica S Elman; Matthew Li; Keyue Shen; Arjun Manrai; Aaron Gabow; Joshua Yarmush; Yunxin Jiao; Anne Fletcher; Jungwoo Lee; Michael J Cima; Martin L Yarmush; Biju Parekkadan
Journal:  Mol Ther       Date:  2014-02-05       Impact factor: 11.454

3.  What's fueling the biotech engine-2012 to 2013.

Authors:  Rob Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2014-01       Impact factor: 54.908

4.  A high throughput MHC II binding assay for quantitative analysis of peptide epitopes.

Authors:  Regina Salvat; Leonard Moise; Chris Bailey-Kellogg; Karl E Griswold
Journal:  J Vis Exp       Date:  2014-03-25       Impact factor: 1.355

5.  A survey of breakthrough therapy designations.

Authors:  Saurabh Rob Aggarwal
Journal:  Nat Biotechnol       Date:  2014-04       Impact factor: 54.908

Review 6.  Molecular pharming's foot in the FDA's door: Protalix's trailblazing story.

Authors:  Tsafrir S Mor
Journal:  Biotechnol Lett       Date:  2015-07-07       Impact factor: 2.461

Review 7.  Recent advances in mammalian protein production.

Authors:  Ashok D Bandaranayake; Steven C Almo
Journal:  FEBS Lett       Date:  2013-12-06       Impact factor: 4.124

8.  Physical stability comparisons of IgG1-Fc variants: effects of N-glycosylation site occupancy and Asp/Gln residues at site Asn 297.

Authors:  Mohammad A Alsenaidy; Solomon Z Okbazghi; Jae Hyun Kim; Sangeeta B Joshi; C Russell Middaugh; Thomas J Tolbert; David B Volkin
Journal:  J Pharm Sci       Date:  2014-04-16       Impact factor: 3.534

9.  Site-specific fatty acid-conjugation to prolong protein half-life in vivo.

Authors:  Sung In Lim; Yukina Mizuta; Akinori Takasu; Young S Hahn; Yong Hwan Kim; Inchan Kwon
Journal:  J Control Release       Date:  2013-06-02       Impact factor: 9.776

10.  Glycosynthase Mutants of Endoglycosidase S2 Show Potent Transglycosylation Activity and Remarkably Relaxed Substrate Specificity for Antibody Glycosylation Remodeling.

Authors:  Tiezheng Li; Xin Tong; Qiang Yang; John P Giddens; Lai-Xi Wang
Journal:  J Biol Chem       Date:  2016-06-10       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.